The Experts below are selected from a list of 31425 Experts worldwide ranked by ideXlab platform

Joseph Hawksworth - One of the best experts on this subject based on the ideXlab platform.

  • enhancement of red blood Cell transfusion compatibility using crispr mediated erythroblast gene editing
    Embo Molecular Medicine, 2018
    Co-Authors: Joseph Hawksworth, Timothy J Satchwell, Marjolein Meinders, Deborah E Daniels, Fiona Regan, Nicole Thornton, Marieangela C Wilson
    Abstract:

    Abstract Regular blood transfusion is the cornerstone of care for patients with red blood Cell (RBC) disorders such as thalassaemia or sickle‐Cell disease. With repeated transfusion, alloimmunisation often occurs due to incompatibility at the level of minor blood group antigens. We use CRISPR‐mediated genome editing of an immortalised human erythroblast Cell line (BEL‐A) to generate multiple enucleation Competent Cell lines deficient in individual blood groups. Edits are combined to generate a single Cell line deficient in multiple antigens responsible for the most common transfusion incompatibilities: ABO (Bombay phenotype), Rh (Rh null ), Kell ( K 0 ), Duffy (Fy null ), GPB (S−s−U−). These Cells can be differentiated to generate deformable reticulocytes, illustrating the capacity for coexistence of multiple rare blood group antigen null phenotypes. This study provides the first proof‐of‐principle demonstration of combinatorial CRISPR‐mediated blood group gene editing to generate customisable or multi‐compatible RBCs for diagnostic reagents or recipients with complicated matching requirements.

  • Enhancement of red blood Cell transfusion compatibility using CRISPR‐mediated erythroblast gene editing
    Wiley, 2018
    Co-Authors: Joseph Hawksworth, Timothy J Satchwell, Marjolein Meinders, Deborah E Daniels, Fiona Regan, Marieangela C Wilson, Nicole M Thornton, Johannes Gg Dobbe, Geert J Streekstra, Kongtana Trakarnsanga
    Abstract:

    Abstract Regular blood transfusion is the cornerstone of care for patients with red blood Cell (RBC) disorders such as thalassaemia or sickle‐Cell disease. With repeated transfusion, alloimmunisation often occurs due to incompatibility at the level of minor blood group antigens. We use CRISPR‐mediated genome editing of an immortalised human erythroblast Cell line (BEL‐A) to generate multiple enucleation Competent Cell lines deficient in individual blood groups. Edits are combined to generate a single Cell line deficient in multiple antigens responsible for the most common transfusion incompatibilities: ABO (Bombay phenotype), Rh (Rhnull), Kell (K0), Duffy (Fynull), GPB (S−s−U−). These Cells can be differentiated to generate deformable reticulocytes, illustrating the capacity for coexistence of multiple rare blood group antigen null phenotypes. This study provides the first proof‐of‐principle demonstration of combinatorial CRISPR‐mediated blood group gene editing to generate customisable or multi‐compatible RBCs for diagnostic reagents or recipients with complicated matching requirements

Marieangela C Wilson - One of the best experts on this subject based on the ideXlab platform.

  • enhancement of red blood Cell transfusion compatibility using crispr mediated erythroblast gene editing
    Embo Molecular Medicine, 2018
    Co-Authors: Joseph Hawksworth, Timothy J Satchwell, Marjolein Meinders, Deborah E Daniels, Fiona Regan, Nicole Thornton, Marieangela C Wilson
    Abstract:

    Abstract Regular blood transfusion is the cornerstone of care for patients with red blood Cell (RBC) disorders such as thalassaemia or sickle‐Cell disease. With repeated transfusion, alloimmunisation often occurs due to incompatibility at the level of minor blood group antigens. We use CRISPR‐mediated genome editing of an immortalised human erythroblast Cell line (BEL‐A) to generate multiple enucleation Competent Cell lines deficient in individual blood groups. Edits are combined to generate a single Cell line deficient in multiple antigens responsible for the most common transfusion incompatibilities: ABO (Bombay phenotype), Rh (Rh null ), Kell ( K 0 ), Duffy (Fy null ), GPB (S−s−U−). These Cells can be differentiated to generate deformable reticulocytes, illustrating the capacity for coexistence of multiple rare blood group antigen null phenotypes. This study provides the first proof‐of‐principle demonstration of combinatorial CRISPR‐mediated blood group gene editing to generate customisable or multi‐compatible RBCs for diagnostic reagents or recipients with complicated matching requirements.

  • Enhancement of red blood Cell transfusion compatibility using CRISPR‐mediated erythroblast gene editing
    Wiley, 2018
    Co-Authors: Joseph Hawksworth, Timothy J Satchwell, Marjolein Meinders, Deborah E Daniels, Fiona Regan, Marieangela C Wilson, Nicole M Thornton, Johannes Gg Dobbe, Geert J Streekstra, Kongtana Trakarnsanga
    Abstract:

    Abstract Regular blood transfusion is the cornerstone of care for patients with red blood Cell (RBC) disorders such as thalassaemia or sickle‐Cell disease. With repeated transfusion, alloimmunisation often occurs due to incompatibility at the level of minor blood group antigens. We use CRISPR‐mediated genome editing of an immortalised human erythroblast Cell line (BEL‐A) to generate multiple enucleation Competent Cell lines deficient in individual blood groups. Edits are combined to generate a single Cell line deficient in multiple antigens responsible for the most common transfusion incompatibilities: ABO (Bombay phenotype), Rh (Rhnull), Kell (K0), Duffy (Fynull), GPB (S−s−U−). These Cells can be differentiated to generate deformable reticulocytes, illustrating the capacity for coexistence of multiple rare blood group antigen null phenotypes. This study provides the first proof‐of‐principle demonstration of combinatorial CRISPR‐mediated blood group gene editing to generate customisable or multi‐compatible RBCs for diagnostic reagents or recipients with complicated matching requirements

Fiona Regan - One of the best experts on this subject based on the ideXlab platform.

  • enhancement of red blood Cell transfusion compatibility using crispr mediated erythroblast gene editing
    Embo Molecular Medicine, 2018
    Co-Authors: Joseph Hawksworth, Timothy J Satchwell, Marjolein Meinders, Deborah E Daniels, Fiona Regan, Nicole Thornton, Marieangela C Wilson
    Abstract:

    Abstract Regular blood transfusion is the cornerstone of care for patients with red blood Cell (RBC) disorders such as thalassaemia or sickle‐Cell disease. With repeated transfusion, alloimmunisation often occurs due to incompatibility at the level of minor blood group antigens. We use CRISPR‐mediated genome editing of an immortalised human erythroblast Cell line (BEL‐A) to generate multiple enucleation Competent Cell lines deficient in individual blood groups. Edits are combined to generate a single Cell line deficient in multiple antigens responsible for the most common transfusion incompatibilities: ABO (Bombay phenotype), Rh (Rh null ), Kell ( K 0 ), Duffy (Fy null ), GPB (S−s−U−). These Cells can be differentiated to generate deformable reticulocytes, illustrating the capacity for coexistence of multiple rare blood group antigen null phenotypes. This study provides the first proof‐of‐principle demonstration of combinatorial CRISPR‐mediated blood group gene editing to generate customisable or multi‐compatible RBCs for diagnostic reagents or recipients with complicated matching requirements.

  • Enhancement of red blood Cell transfusion compatibility using CRISPR‐mediated erythroblast gene editing
    Wiley, 2018
    Co-Authors: Joseph Hawksworth, Timothy J Satchwell, Marjolein Meinders, Deborah E Daniels, Fiona Regan, Marieangela C Wilson, Nicole M Thornton, Johannes Gg Dobbe, Geert J Streekstra, Kongtana Trakarnsanga
    Abstract:

    Abstract Regular blood transfusion is the cornerstone of care for patients with red blood Cell (RBC) disorders such as thalassaemia or sickle‐Cell disease. With repeated transfusion, alloimmunisation often occurs due to incompatibility at the level of minor blood group antigens. We use CRISPR‐mediated genome editing of an immortalised human erythroblast Cell line (BEL‐A) to generate multiple enucleation Competent Cell lines deficient in individual blood groups. Edits are combined to generate a single Cell line deficient in multiple antigens responsible for the most common transfusion incompatibilities: ABO (Bombay phenotype), Rh (Rhnull), Kell (K0), Duffy (Fynull), GPB (S−s−U−). These Cells can be differentiated to generate deformable reticulocytes, illustrating the capacity for coexistence of multiple rare blood group antigen null phenotypes. This study provides the first proof‐of‐principle demonstration of combinatorial CRISPR‐mediated blood group gene editing to generate customisable or multi‐compatible RBCs for diagnostic reagents or recipients with complicated matching requirements

Timothy J Satchwell - One of the best experts on this subject based on the ideXlab platform.

  • enhancement of red blood Cell transfusion compatibility using crispr mediated erythroblast gene editing
    Embo Molecular Medicine, 2018
    Co-Authors: Joseph Hawksworth, Timothy J Satchwell, Marjolein Meinders, Deborah E Daniels, Fiona Regan, Nicole Thornton, Marieangela C Wilson
    Abstract:

    Abstract Regular blood transfusion is the cornerstone of care for patients with red blood Cell (RBC) disorders such as thalassaemia or sickle‐Cell disease. With repeated transfusion, alloimmunisation often occurs due to incompatibility at the level of minor blood group antigens. We use CRISPR‐mediated genome editing of an immortalised human erythroblast Cell line (BEL‐A) to generate multiple enucleation Competent Cell lines deficient in individual blood groups. Edits are combined to generate a single Cell line deficient in multiple antigens responsible for the most common transfusion incompatibilities: ABO (Bombay phenotype), Rh (Rh null ), Kell ( K 0 ), Duffy (Fy null ), GPB (S−s−U−). These Cells can be differentiated to generate deformable reticulocytes, illustrating the capacity for coexistence of multiple rare blood group antigen null phenotypes. This study provides the first proof‐of‐principle demonstration of combinatorial CRISPR‐mediated blood group gene editing to generate customisable or multi‐compatible RBCs for diagnostic reagents or recipients with complicated matching requirements.

  • Enhancement of red blood Cell transfusion compatibility using CRISPR‐mediated erythroblast gene editing
    Wiley, 2018
    Co-Authors: Joseph Hawksworth, Timothy J Satchwell, Marjolein Meinders, Deborah E Daniels, Fiona Regan, Marieangela C Wilson, Nicole M Thornton, Johannes Gg Dobbe, Geert J Streekstra, Kongtana Trakarnsanga
    Abstract:

    Abstract Regular blood transfusion is the cornerstone of care for patients with red blood Cell (RBC) disorders such as thalassaemia or sickle‐Cell disease. With repeated transfusion, alloimmunisation often occurs due to incompatibility at the level of minor blood group antigens. We use CRISPR‐mediated genome editing of an immortalised human erythroblast Cell line (BEL‐A) to generate multiple enucleation Competent Cell lines deficient in individual blood groups. Edits are combined to generate a single Cell line deficient in multiple antigens responsible for the most common transfusion incompatibilities: ABO (Bombay phenotype), Rh (Rhnull), Kell (K0), Duffy (Fynull), GPB (S−s−U−). These Cells can be differentiated to generate deformable reticulocytes, illustrating the capacity for coexistence of multiple rare blood group antigen null phenotypes. This study provides the first proof‐of‐principle demonstration of combinatorial CRISPR‐mediated blood group gene editing to generate customisable or multi‐compatible RBCs for diagnostic reagents or recipients with complicated matching requirements

Lusânia Maria Greggi Antunes - One of the best experts on this subject based on the ideXlab platform.

  • The cosmetic dye quinoline yellow causes DNA damage in vitro.
    Mutation research. Genetic toxicology and environmental mutagenesis, 2014
    Co-Authors: Farah Maria Drumond Chequer, Vinícius De Paula Venâncio, Maíra Rocha De Souza Prado, Luiz Raimundo Campos Da Silva E Cunha Junior, Thiago Mescoloto Lizier, Maria Valnice Boldrin Zanoni, Rommel Rodríguez Burbano, Maria De Lourdes Pires Bianchi, Lusânia Maria Greggi Antunes
    Abstract:

    Quinoline yellow (QY) is a chinophthalon derivative used in cosmetic compositions for application to the skin, lips, and/or body surface. However, regulatory data about the genotoxicity and/or mutagenicity of this compound are still controversial. Therefore, this work evaluated the genotoxicity of QY using the comet assay and the cytokinesis-block micronucleus cytome assay (CBMN-Cyt) in the metabolically Competent Cell line HepG2, which closely mimics phase I metabolism. This research also identified the products formed after electrochemical oxidation of the QY dye, which simulates hepatic biotransformation. The primary products generated after the oxidation process were analyzed by High Performance Liquid Chromatography coupled with a Diode Array Detector (HPLC/DAD), which detected the production of 4,4'-diaminodiphenylmethane, 2-methoxy-5-methylaniline and 4,4'-oxydianiline. The results demonstrated that low (from 0.5 to 20 μg mL(-1)) QY concentrations were genotoxic in HepG2 Cells on both assays and those harmful compounds were detected after the oxidation process. Our findings suggest that this colorant could cause harmful effects to humans if it is metabolized or absorbed through the skin.